<![CDATA[SPPI op idag?]]>Spectrum Pharmaceuticals Announces the USPTO Has Granted Five-Year Extension for FOLOTYN(R) Patent

FOLOTYN® (pralatrexate injection) is the first therapeutic to have been approved for peripheral T-cell lymphoma (PTCL), in September 2009
FOLOTYN net sales were approximately $50 million in 2011
Spectrum acquired FOLOTYN through acquisition of Allos Therapeutics on September 5, 2012

Access Denied

favicon

(www.cnbc.com)

]]>https://dev.proinvestor.com/forum/topic/436785/sppi-op-idagRSS for NodeTue, 28 Jul 2026 02:13:30 GMTMon, 08 Oct 2012 09:38:59 GMT60